Top Story

Cutaneous leishmaniasis incidence in Israel increased 10-fold from 2001-2012

October 23, 2014

After a 15-year period of decreased incidence of cutaneous leishmaniasis in Israel, a recent resurgence of the disease appears to have occurred in the southern, central and northern parts of the country, according to recent findings.

In the study, researchers evaluated surveillance data on cutaneous leishmaniasis conducted by the Israeli Ministry of Health. A computerized notification system compiled information on cases, with reports generated for 15 regional health districts across Israel. The researchers assessed all cases of recent onset cutaneous leishmaniasis from January 2001 to December 2012. Reviewed cases only included the civilian population, not the Israeli military. The researchers used annual population estimates to arrive at the denominators used to calculate crude and specific incidence rates per 100,000 persons based on age, population group and district.

figure Health Care Legislative and Regulatory Update

Reducing the burden of Medicare's physician quality-reporting system

October 23, 2014
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of…

Potential drug decreased viral load in patients with various HCV genotypes

October 23, 2014
Interim results from an ongoing clinical trial revealed that a microRNA therapeutic was well-tolerated and safe for the treatment of hepatitis C virus infection…
In the Journals

Children with enterovirus more likely to develop type 1 diabetes

October 23, 2014
Children who have had enterovirus are at increased risk for developing type 1 diabetes compared with children who have not had the virus, according to recent findings…
More News Headlines »

HCV Consults: Volume 1, Number 3

This activity is supported by educational grants from AbbVie and Genentech, Inc.

More »
Meeting News Coverage Video

New and upcoming therapies for the treatment of HCV

October 21, 2014
PHILADELPHIA — In this exclusive video interview, Paul Y. Kwo, MD, HCV Next Editorial Board member, discusses…
More »

Advances in Pharmacokinetic Enhancers in HIV Treatment: What You Need to Know to Optimize Outcomes

This activity is supported by an educational grant from Bristol-Myers Squibb.

Protease inhibitors (PIs) have played an instrumental role in decreasing mortality andmorbidity among HIV-infected…
More »